Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00932893 · BASELINE

Baseline characteristics

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene · Source last updated 2017-01-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      173
    2. group Id
      BG001
      value
      174
    3. group Id
      BG002
      value
      347
    units
    Participants
groups
  1. description
    Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
    id
    BG000
    title
    Crizotinib
  2. description
    Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
    id
    BG001
    title
    Chemotherapy
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          13.1
          value
          50.3
        2. group Id
          BG001
          spread
          13.0
          value
          49.8
        3. group Id
          BG002
          spread
          13.0
          value
          50.0
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          98
        2. group Id
          BG001
          value
          95
        3. group Id
          BG002
          value
          193
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          75
        2. group Id
          BG001
          value
          79
        3. group Id
          BG002
          value
          154
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Gender
    unit Of Measure
    Participants
population Description
Full analysis set (FAS) included all participants who were randomized to study treatment.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      173
    2. group Id
      BG001
      value
      174
    3. group Id
      BG002
      value
      347
    units
    Participants
groups
  1. description
    Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
    id
    BG000
    title
    Crizotinib
  2. description
    Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
    id
    BG001
    title
    Chemotherapy
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          13.1
          value
          50.3
        2. group Id
          BG001
          spread
          13.0
          value
          49.8
        3. group Id
          BG002
          spread
          13.0
          value
          50.0
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          98
        2. group Id
          BG001
          value
          95
        3. group Id
          BG002
          value
          193
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          75
        2. group Id
          BG001
          value
          79
        3. group Id
          BG002
          value
          154
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Gender
    unit Of Measure
    Participants
population Description
Full analysis set (FAS) included all participants who were randomized to study treatment.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice